{"id":212397,"date":"2025-12-03T02:12:09","date_gmt":"2025-12-03T02:12:09","guid":{"rendered":"https:\/\/www.europesays.com\/ie\/212397\/"},"modified":"2025-12-03T02:12:09","modified_gmt":"2025-12-03T02:12:09","slug":"cvs-to-pay-37-8-million-to-settle-claims-over-insulin-pens","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/ie\/212397\/","title":{"rendered":"CVS to pay $37.8 million to settle claims over insulin pens"},"content":{"rendered":"<ul data-testid=\"Summary\" class=\"summary-module__summary__QjADA\">\n<li data-testid=\"Body\" class=\"text-module__text__0GDob text-module__dark-grey__UFC18 text-module__regular__qJJtA text-module__small__sph8i body-module__base__o--Cl body-module__small_body__gOmDf summary-module__point__UgXPz\">CVS said to obtain reimbursement for excess insulin pens<\/li>\n<li data-testid=\"Body\" class=\"text-module__text__0GDob text-module__dark-grey__UFC18 text-module__regular__qJJtA text-module__small__sph8i body-module__base__o--Cl body-module__small_body__gOmDf summary-module__point__UgXPz\">Whistleblower to share settlement proceeds<\/li>\n<li data-testid=\"Body\" class=\"text-module__text__0GDob text-module__dark-grey__UFC18 text-module__regular__qJJtA text-module__small__sph8i body-module__base__o--Cl body-module__small_body__gOmDf summary-module__point__UgXPz\">CVS says insulin pen billing challenges being addressed<\/li>\n<\/ul>\n<p>NEW YORK, Dec 2 (Reuters) &#8211; CVS Health <a data-testid=\"Link\" target=\"_blank\" referrerpolicy=\"no-referrer-when-downgrade\" href=\"https:\/\/www.reuters.com\/markets\/companies\/CVS.N\" rel=\"noopener nofollow\" class=\"text-module__text__0GDob text-module__inherit-color__PhuPF text-module__inherit-font__1P1hv text-module__inherit-size__EyiQW link-module__link__INqxZ link-module__underline_default__-okuC link-module__with-icon__qlg76\">(CVS.N), opens new tab<\/a> will pay $37.76 million to settle allegations it dispensed too many insulin pens to patients, and then obtained improper reimbursements from Medicare, Medicaid and other government healthcare programs, U.S. Attorney Jay Clayton in Manhattan said on Tuesday.<\/p>\n<p>The settlement resolves charges that CVS violated the federal False Claims Act between January 1, 2010 and December 31, 2020 by dispensing more insulin pens than doctors prescribed, obtaining reimbursements for premature refills, and underreporting how much insulin its pharmacies dispensed.<\/p>\n<p data-testid=\"promo-box\" class=\"text-module__text__0GDob text-module__dark-grey__UFC18 text-module__regular__qJJtA text-module__small__sph8i body-module__base__o--Cl body-module__small_body__gOmDf article-body-module__promo-box__hVl8h\"> Sign up  <a data-testid=\"Link\" referrerpolicy=\"no-referrer-when-downgrade\" href=\"https:\/\/www.reuters.com\/world\/cvs-pay-378-million-settle-claims-over-insulin-pens-2025-12-02\/undefined?location=article-paragraph&amp;redirectUrl=%2Fworld%2Fcvs-pay-378-million-settle-claims-over-insulin-pens-2025-12-02%2F\" class=\"text-module__text__0GDob text-module__inherit-color__PhuPF text-module__inherit-font__1P1hv text-module__inherit-size__EyiQW link-module__link__INqxZ link-module__underline_default__-okuC\" rel=\"nofollow noopener\" target=\"_blank\">here.<\/a><\/p>\n<p>CVS allegedly instructed pharmacy staff to report the maximum days-of-supply allowed when dispensing full insulin pen cartons, to ensure it could fill prescriptions as quickly as possible and that reimbursement claims would be approved.<\/p>\n<p>Patients with diabetes use the pens to give themselves insulin shots.<\/p>\n<p>The payout includes $24.45 million to the federal government, and the remainder to various U.S. states, Clayton said.<\/p>\n<p>CVS, based in Woonsocket, Rhode Island, said in a statement that insulin pen billing &#8220;has long been a challenge for pharmacies&#8221; because of labeling changes, variable dosing and packaging, and varying payor supply limits.<\/p>\n<p>&#8220;In recent years, the evolution of PBMs (pharmacy benefit managers) and payor practices to account for insulin pen packaging and other technological enhancements have helped alleviate some of these challenges,&#8221; CVS said. &#8220;With this settlement, we\u2019re pleased to put this issue behind us.&#8221;<\/p>\n<p>Tuesday&#8217;s settlement resolves a U.S. Department of Justice lawsuit and several whistleblower cases.<\/p>\n<p>The first case was brought in 2018 by Adam Rahimi, a CVS pharmacist. Whistleblowers will receive 19.5% of the settlement amount, with Rahimi receiving most of it, his lawyers said.<\/p>\n<p data-testid=\"SignOff\" class=\"text-module__text__0GDob text-module__dark-grey__UFC18 text-module__regular__qJJtA text-module__extra_small__8Buss body-module__full_width__kCIGb body-module__extra_small_body__Bfz20 sign-off-module__text__LQAMP\">Reporting by Jonathan Stempel in New York; Editing by Chizu Nomiyama and Bill Berkrot<\/p>\n<p data-testid=\"Body\" dir=\"ltr\" class=\"text-module__text__0GDob text-module__dark-grey__UFC18 text-module__regular__qJJtA text-module__small__sph8i body-module__base__o--Cl body-module__small_body__gOmDf article-body-module__element__5eCce article-body-module__trust-badge__5mS3f\">Our Standards: <a data-testid=\"Link\" target=\"_blank\" referrerpolicy=\"no-referrer-when-downgrade\" href=\"https:\/\/www.thomsonreuters.com\/en\/about-us\/trust-principles.html\" rel=\"noopener nofollow\" class=\"text-module__text__0GDob text-module__dark-grey__UFC18 text-module__medium__2Rl30 text-module__small__sph8i link-module__link__INqxZ link-module__underline_default__-okuC link-module__with-icon__qlg76\">The Thomson Reuters Trust Principles., opens new tab<\/a><\/p>\n<p><a href=\"https:\/\/www.reutersagency.com\/en\/licensereuterscontent\/?utm_medium=rcom-article-media&amp;utm_campaign=rcom-rcp-lead\" target=\"_blank\" dir=\"ltr\" class=\"button-module__link__A3sD0 button-module__secondary__70gBu button-module__round__QDFgq button-module__w_auto__Sem-F\" data-testid=\"LicenceContentButton\" rel=\"nofollow noopener\">Purchase Licensing Rights<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"CVS said to obtain reimbursement for excess insulin pens Whistleblower to share settlement proceeds CVS says insulin pen&hellip;\n","protected":false},"author":2,"featured_media":212398,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[275],"tags":[82519,82794,82500,85474,82559,82530,87652,87221,82802,83630,82531,87219,18,86743,45748,87209,135,475,474,87211,87648,87649,87212,87215,19,17,82798,721,82565,82524,87647,87220,82790,88152,82510,83002,82964,82558,87206,88225,87203,88232,115907,115908,107,115910,115911,115909],"class_list":{"0":"post-212397","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-healthcare","8":"tag-amers","9":"tag-clj","10":"tag-cmpny","11":"tag-crim","12":"tag-destlita","13":"tag-destocabsm","14":"tag-destohlt","15":"tag-destoinn","16":"tag-destolit","17":"tag-destoprod","18":"tag-destousbsm","19":"tag-destoushem","20":"tag-eire","21":"tag-fraud1","22":"tag-gen","23":"tag-hea","24":"tag-health","25":"tag-health-care","26":"tag-healthcare","27":"tag-heca","28":"tag-hfac","29":"tag-hfac1","30":"tag-hlthse","31":"tag-hpas","32":"tag-ie","33":"tag-ireland","34":"tag-judic","35":"tag-legal","36":"tag-mtpix","37":"tag-namer","38":"tag-nrlpaohlt","39":"tag-nrlpaoinn","40":"tag-nrlpaolit","41":"tag-nrlpaoprod","42":"tag-publ","43":"tag-pxp","44":"tag-regs","45":"tag-reuters-legal","46":"tag-rhpihealthcare-providers","47":"tag-rhpilawsuits","48":"tag-topicpharma-healthcare-business-health","49":"tag-topicpharma-healthcare-policy-regulation","50":"tag-topicworld-us-new-york","51":"tag-topicworld-us-rhode-island","52":"tag-us","53":"tag-usany","54":"tag-usari","55":"tag-uscnyc"},"share_on_mastodon":{"url":"","error":"Validation failed: Text character limit of 500 exceeded"},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/posts\/212397","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/comments?post=212397"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/posts\/212397\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/media\/212398"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/media?parent=212397"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/categories?post=212397"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/tags?post=212397"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}